TRADING IN SENZIME’S SHARES ON NASDAQ STOCKHOLM COMMENCES TODAY

Uppsala, 30 June 2021. Senzime AB (publ) announces that the company’s shares are admitted for trading on Nasdaq Stockholm's main market today.

“It’s fantastic milestone for Senzime to be listed on Nasdaq Stockholm's main market. Senzime is today a global company with its own sales force in US and Germany, we have licensees in Japan and Europe and we have distributors in other important markets. We have delivered hundreds of TetraGraph systems to operating rooms worldwide and new clinical guidelines support our cutting-edge technology that helps eliminate the many millions of anesthesia-related complications that patients experience each year’’, said Pia Renaudin, CEO of Senzime.

The shares will be traded on the Nasdaq Stockholm main market under the same ticker (SEZI) and ISIN-code (SE0002478776). There is no offering or issue of new shares in connection with the list change, and shareholders in Senzime do not need to take any actions.

N.B. English translation is for convenience purposes only.

For further information, please contact:

Pia Renaudin, CEO of Senzime AB 
Phone: +46 (0) 70-813 34 17, e-post: pia.renaudin@senzime.com
 
Erik Bergman, CFO
Phone: +46 (0) 73-258 81 59, e-mail: erik.bergman@senzime.com

About Senzime

Senzime develops and markets CE- and FDA cleared patient monitoring systems driven by unique algorithms and sensors to closely monitor patients under anesthesia. TetraGraph is a system that digitally and continuously measures the degree of neuromuscular blockade in the patient. The goal is improved clinical precision and simplified management in healthcare. By preventing complications and enabling healthcare professionals to follow guidelines and drug recommendations, TetraGraph can contribute to shorten hospital stays and lower healthcare costs. The vision is a world without anesthesia related complications, where everyone wakes up safely after surgery. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 15 billion. The company's shares are listed on Nasdaq Stockholm’s main market (ticker SEZI) since June, 30 2021. www.senzime.com

Attachments

TRADING IN SENZIME’S SHARES ON NASDAQ STOCKHOLM COMMENCES TODAY

Contact us

Want to know more?

How can Senzime’s innovative patient monitoring solutions help to eliminate in-hospital complications?
Contact us today.

Contact us now